Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations

by Andrew J. Piper-Vallillo, MD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Published 2021-03-01

Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα

by Radhakrishnan Sridhar, Hisashi Takei, Riyaz Syed, Ikei S. Kobayashi, Liu Bee Hui, Ahmed Kamal, Daniel G. Tenen, Susumu S. Kobayashi
Published 2018-08-01

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells

by Yumi Fujimoto, Tomoko Yamamori Morita, Akihiro Ohashi, Hiroshi Haeno, Yumi Hakozaki, Masanori Fujii, Yukie Kashima, Susumu S. Kobayashi, Toru Mukohara
Published 2020-12-01

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

by Sho Watanabe, Yasushi Goto, Hiroyuki Yasuda, Takashi Kohno, Noriko Motoi, Yuichiro Ohe, Hiroyoshi Nishikawa, Susumu S. Kobayashi, Kazuyoshi Kuwano, Yosuke Togashi
Published 2021-03-01

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

by Pedro E.N.S. Vasconcelos, MS, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Published 2021-03-01

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

by Andrew J. Piper-Vallillo, MD, Brian T. Halbert, MD, Deepa Rangachari, MD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Published 2020-11-01

CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma.

by Yi Cai, Ayako Hirata, Sohei Nakayama, Paul A VanderLaan, Elena Levantini, Mihoko Yamamoto, Hideyo Hirai, Kwok-Kin Wong, Daniel B Costa, Hideo Watanabe, Susumu S Kobayashi
Published 2015-01-01

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

by Pedro E.N.S. Vasconcelos, MS, Carol Gergis, MS, Hollis Viray, MD, Andreas Varkaris, MD, PhD, Masanori Fujii, MD, PhD, Deepa Rangachari, MD, Paul A. VanderLaan, MD, PhD, Ikei S. Kobayashi, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD
Published 2020-09-01